- LIXTE Biotechnology Holdings Inc LIXT noted that a team of scientists reported that in three difficult-to-treat cancer types, LIXTE's lead compound, LB-100, combined with an inhibitor of the WEE1 kinase, causes unexpectedly effective cancer cell killing.
- Most surprisingly, when cancer cells acquire resistance to this combination therapy, they have highly reduced cancer-causing capacity in animal models.
- This observation indicates that LB-100 combination therapy can force cells to give up their cancer-causing properties to acquire drug resistance.
- Related: Lixte Biotech Shares Jump Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers.
- John Kovach, CEO and Founder of LIXTE and a co-author of the report, said the treatment of cancer cells with Lixte's lead clinical compound, LB-100, rather than inhibiting, further stimulates the signals that drive cancer cell proliferation, but paradoxically, impeding cell proliferation.
- Dr. Kovach continued, "The authors also show that combination of LB-100 with an inhibitor of WEE1, a regulator of stress responses in the cell, leads to highly efficient cancer cell death in three hard-to-treat cancer models: colorectal, pancreatic, and bile duct carcinomas."
- The combination of LB-100 and WEE1 inhibition suppressed the growth of patient-derived tumors refractory to conventional therapies and was associated with only modest toxicity in animal models.
- Price Action: LIXT shares are up 146% at $2.00 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
